The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes

Bortezomib (BTZ) is a first-in-class proteasome inhibitor approved for the therapy of multiple myeloma that also displays unique regulatory activities on immune cells. The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme exerting potent immunoregulatory effects when ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondanelli, Giada, Albini, Elisa, Pallotta, Maria T., Volpi, Claudia, Chatenoud, Lucienne, Kuhn, Chantal, Fallarino, Francesca, Matino, Davide, Belladonna, Maria L., Bianchi, Roberta, Vacca, Carmine, Bicciato, Silvio, Boon, Louis, Ricci, Giovanni, Grohmann, Ursula, Puccetti, Paolo, Orabona, Ciriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390013/
https://www.ncbi.nlm.nih.gov/pubmed/28450863
http://dx.doi.org/10.3389/fimmu.2017.00428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390013/
https://www.ncbi.nlm.nih.gov/pubmed/28450863
http://dx.doi.org/10.3389/fimmu.2017.00428

Ejemplares similares